Avemar immune booster Review Article
We trade genuine Hungarian brand product - AVEMAR (known in USA under the generic version "AVE", Avemar Ave, Ave Avemar ). Avemar is recommended for patients suffering from malignant tumors as a supplement to clinical oncology treatment (surgery, radiotherapy, chemotherapy, immunotherapy etc.). Avemar cancer protector supplement is the product of industrial fermentation of wheat germ, possesses unique cancer-fighting characteristics. Avemar is used to inhibit tumor dissemination and proliferation during and after radiation, surgery or chemotherapy. It is efficient in various human cancers, cultures of in vitro grown cells, in some autoimmune conditions or in the prevention of chemical carcinogenesis. In 1941, Huller and Stern analyzed chemical changes in wheat germ. In 1960, Albert Szent-Gyorgyi concluded that deficiency in ascorbic acid and methoxy groups, such as benzoquinones, leads to malignant diseases.
He suggested that by consuming these ingredients, it is possible to boost significantly the immune system. In 1992, a Hungarian scientist M?t? Hidv?gi started working on natural quinone concentrate, using the ideas of Albert Szent-Gyorgyi as a basis. A researcher Rita T?m?sk?zi-Farkas later joined him. Continue reading...
||Add to basket
|NEW !!! 1 month supply
||AVEMAR in tablets - 150 tab
shipping: USD 24.00
|NEW !!! 2 month supply
||AVEMAR in tablets - 300 tab
shipping: USD 36.00
|1 box (1 x 510 g)
||30 packets x 17g ($4.3 per packet}
shipping: USD 47.00
|2 boxes (2 x 510 g)
||60 packets x 17g ($4.2 per packet)
shipping: USD 78.00
|3 boxes (3 x 510 g)
||90 packets x 17g ($4.1 per packet)
shipping: USD 99.00
In 1995, ???? K?roly Lapis, B?la Szende, Erzs?bet R?s? found that wheat germ extract significantly inhibited the growth of cancer cells. Moreover, in combination with chemotherapy it prevented metastasis processes. The results were tested on several thousands of animals. In 1997, Professor M?t? Hidv?gi and his colleagues started process engineering and industrial extract release.
The final engineering developments have been made in Israel. In 1998 Avemar® was presented in Budapest and Tel Aviv. In 2002 Avemar® was registered in Hungary as a "medical nutrient for cancer patients." In 2003, Czech Republic became the second country, where Avemar® was officially legalized as a nutrient. In 2007, in M.D. Anderson Cancer Center, USA, serious clinical trials were conducted, and their results were published in the scientific work of Gary L. Johanning, PhD and Feng Wang-Johanning, MD, PhD.
One hundred and four patients with colorectal cancer (colon cancer) received adjuvant therapy, including Avemar®. As compared to the control group, where survival rate was 57.7%, in the group receiving Avemar® survival rate reached 83.3%. No side effects were observed. Avemar® proved to be very efficient in the regulation of blood sugar.
In administration of megadoses of vitamin C in combination with Avemar®, the results were significantly more impressive than in administration of vitamin C alone (the drugs were alternated, since they can’t be used concomitantly). Recently, many studies have been done on Avemar®. Remarkable results were achieved in treating breast cancer in women. The effect surpassed the performance of the leading drugs used in the treatment of this type of cancer. Avemar® was granted the GRAS status (Generally Recognized As Safe) by the FDA.
Avemar® is a molecular composite product derived from wheat germ by fermentation and biotechnological transformation. After concentration of the elements, the substance undergoes medical standardization, whereby the active ingredients take encapsulated form owing to various physico-chemical processes. At the end, a semi-synthetic, semi-natural substance takes the form of granules, which should be dissolved in water and then swallowed. The structure of Avemar® contains extra molecular components.
Administration of Avemar® is recommended to patients suffering from malignant tumors as adjuvant therapy complementing conventional treatment: surgery, radiotherapy, chemotherapy and immunotherapy. Avemar® treats cancer, immune disorders and autoimmune diseases. Avemar® is effective in the treatment of gastric, breast, prostate, cervix and lung cancers.
The product should be administered once a day an hour before a meal. In oncological diseases, the recommended dose amounts to 1 sachet per day (17 g) for normal weight patients. In case if a patient weighs more than 90 kg, it is recommended to take the medicine twice a day (1 sachet an hour before breakfast and 1 sachet an hour before dinner). One sachet is dissolved in a cup of cold noncarbonated water (200-250 ml) and then taken after thorough mixing.
It is prohibited to administer Avemar® concomitantly with vitamin C. The interval should in no event be less than 2 hours. Avemar® also acts as an antioxidant and immune system booster, and it considerably improves the quality of life in severe diseases. Avemar® can be taken in diabetes, but under medical supervision.
1. It is prohibited to take the product during pregnancy and lactation;
2. The patients with transplanted organs or other transplants are not allowed to take the drug;
3. The medicinal agent is prohibited in gastric bleeding, severe gastritis, colitis, ulcers, intestinal inflammation, and in food absorption malfunctioning;
4. The drug is prohibited in gluten allergy or hypersensitivity;
5. It is prohibited to take the drug in hereditary fructose intolerance or hypersensitivity to any of the ingredients
6. Children under 14 are not allowed to take Avemar®
7. In the event of any radiological gastric tests, pondering the use of barium sulfate, administration of Avemar® should be discontinued 2 days before the test and 2 days after it.
1. Fermented wheat germ extract reduces chemotherapy-induced febrile neutropenia in pediatric cancer patients.
Garami M, Schuler D, Babosa M, Borgulya G, Hauser P, M?ller J, Paksy A, Szab? E, Hidv?gi M, Fekete G.
Second Department of Pediatrics, School of Medicine, Semmelweis University, Budapest, Hungary. J Pediatr Hematol Oncol. 2004 Oct; 26(10):631-5.
An open-label, matched-pair pilot clinical trial was aimed at comparing the efficacy of concomitant administration of Avemar® and anticancer therapies with an anticancer monotherapy. Twenty two patients were enrolled in the study. The results demonstrated that concomitant administration of Avemar® and cytotoxic drugs reduces the incidence of treatment-related febrile neutropenia in children with solid cancers. During the follow-up period there was no progression of the malignancy.
2. The efficacy of tamoxifen in estrogen receptor-positive breast cancer cells is enhanced by a medical nutriment
Marcsek Z, Kocsis Z, Jakab M, Szende B, Tompa A.
National Institute of Chemical Safety, "J?zsef Fodor" National Center for Public Health, Budapest, Hungary.
Cancer Biother Radiopharm. 2004 Dec; 19(6):746-53.
During another study, the effect of a combination of Tamoxifen and Avemar® therapies was investigated on breast cancer cells. The results showed that Tamoxifen (1 nM) alone didn't have any effect on the amount of apoptotic cells, while Avemar® (625 µg/ml) considerably increased apoptosis after only 48 hours of treatment. Concomitant administration of Tamoxifen and Avemar® significantly increased the rate of apoptosis in 24 hours after treatment initiation. A conclusion was made that supplementary administration of Avemar® can enhance the therapeutic effect of Tamoxifen in breast cancer treatment.
3. A medical nutriment has supportive value in the treatment of colorectal cancer.
Jakab F, Shoenfeld Y, Balogh A, Nichelatti M, Hoffmann A, Kah?n Z, Lapis K, Mayer A, S?py P, Szentp?tery F, Telekes A, Thurz? L, V?gv?lgyi A, Hidv?gi M.
Department of Surgery and Vascular Surgery, Uzsoki Teaching Hospital of Budapest, Hungary.
Br J Cancer. 2003 Aug 4; 89(3):465-9.
Another study was designed to investigate an antimetastatic activity of Avemar®. An open-label cohort trial enrolled 66 colorectal cancer patients. The results indicated that continuous supplementation of anticancer therapies with Avemar® for over half a year is beneficial to patients suffering from colorectal cancer in terms of both progression-free and overall survival. The incidence of progression-related events considerably decreased in the group receiving Avemar®.
4. Safety studies regarding a standardized extract of fermented wheat germ.
Heimbach JT, Sebestyen G, Semjen G, Kennepohl E
JHeimbach LLC, Port Royal, Virginia 22535, USA.
Int J Toxicol. 2007 May-Jun; 26(3): 253-9.
The results of various toxicological and clinical studies of Avemar® confirmed its safety if taken as a dietary supplement. No evidence of mutagenic or genotoxic properties were observed either in vitro or in vivo. Thus, administration of Avemar® as a complementary drug didn’t reveal any evidence of toxicity in cancer patients, and it also demonstrated reduction in the side effects of chemotherapy at doses of 8.5 g/day. Moreover, Avemar® is thought not to cause adverse effects if used as an ingredient in dietary supplements under the conditions of intended use.
Avemar immune booster Review Article